Related Experiment Video
Updated: May 13, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Trametinib (GSK1120212) in the treatment of melanoma
April K S Salama1, Kevin B Kim
1Duke University Medical Center, Division of Medical Oncology, Durham, NC, USA.
Introduction:
The discovery of somatic mutations in melanoma has advanced our knowledge of the biology of the disease. The mutations, such as those in NRAS, BRAF, GNAQ and GNA11, promote the growth of melanoma cells in most part through the mitogen-activated protein kinase (MAPK) pathway. Understanding the molecular pathways of some of these mutations has resulted in the successful development of selective BRAF inhibitors. Yet, a cure for advanced melanoma is far from reality. Targeting MAPK/ERK kinase (MEK), an essential intermediary kinase protein within the MAPK pathway, may be a promising way to treat patients with BRAF or other genomic mutation.
Areas Covered:
The authors discuss the MAPK pathway in melanoma and review the preclinical and clinical studies of the MEK inhibitor, trametinib , in melanoma. They also discuss the potential of using trametinib in the targeted therapy of advanced melanoma.
Expert Opinion:
Studies have demonstrated the activity of trametinib in BRAF-mutant melanoma, suggesting that it could be a very reasonable alternative to BRAF inhibitors for these patients. Current clinical investigations have shown great promise with the combination of trametinib and dabrafenib in patients with BRAF-mutant melanoma; a number of clinical trials of trametinib in combination with other targeted drugs are underway.
Insights
Targeting the MAPK/ERK kinase (MEK) pathway with trametinib shows promise for advanced melanoma. This MEK inhibitor is effective in BRAF-mutant melanoma and is being investigated in combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Somatic mutations in melanoma, including NRAS, BRAF, GNAQ, and GNA11, drive tumor growth via the mitogen-activated protein kinase (MAPK) pathway.
- Targeted therapies, such as BRAF inhibitors, have been developed based on understanding these molecular pathways.
- Despite advancements, a cure for advanced melanoma remains elusive, highlighting the need for alternative therapeutic strategies.
Purpose of the Study:
- To review the role of the MAPK pathway in melanoma pathogenesis.
- To evaluate the preclinical and clinical efficacy of the MEK inhibitor, trametinib, in melanoma treatment.
- To explore the potential of trametinib as a targeted therapy for advanced melanoma.
Main Methods:
- Review of preclinical studies on trametinib in melanoma models.
- Analysis of clinical trial data investigating trametinib in melanoma patients.
- Discussion of trametinib's mechanism of action within the MAPK pathway.
Main Results:
- Trametinib demonstrates significant activity in BRAF-mutant melanoma.
- The drug presents a viable alternative to BRAF inhibitors for specific patient populations.
- Combination therapy with trametinib and dabrafenib shows promising results in clinical investigations.
Conclusions:
- Targeting the MAPK/ERK kinase (MEK) pathway with trametinib is a promising strategy for advanced melanoma.
- Trametinib offers a potential alternative or complementary treatment to BRAF inhibitors.
- Ongoing clinical trials are exploring trametinib in combination with other targeted agents for enhanced melanoma treatment.
